The U.S. benign prostatic hyperplasia (BPH) procedures is expected to grow at a CAGR of 4.2% during 2017-2023.
By 2023, the number of BPH procedures performed in the U.S. is expected to reach 215,584. Growing aging population, rising prevalence of BPH disorders, technological advancements in the BPH procedures and increasing awareness about the BPH disorders and treatments available are the major factors driving the adoption of BPH procedures in the U.S.
Download Report Sample at: https://www.psmarketresearch.com/market-analysis/us-bph-procedures/report-sample
The advanced research and development activities has led to the development of technologically advanced BPH devices and therapies. Prostatic urethral lift (Urolift system) and targeted sterile water vapor therapy (Rezūm) are some of the recent technological therapies launched for BPH management. Rezūm therapy is a minimally invasive procedure that uses steam in the treatment of enlarged prostate and is currently available in the U.S. These therapies can be performed in a clinic or at an outpatient facility, and thereby reduces the cost associated with hospital stay and surgeries.
Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=us-bph-procedures
Key player in the U.S. BPH procedures are introducing new advanced products for BPH treatment and gaining public and private insurance coverage. For instance, in May 2017, NeoTract, Inc. announced that its patent UroLift system has received insurance coverage for the treatment of BPH from Cigna Insurance Services Co., a global health service company that provides insurance to over 14 million Americans.
Some of the other key players providing BPH procedures in the U.S. include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC., Convergent Laser Technologies.
P&S Market Research
347, 5th Ave.
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)